Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Carfilzomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 16 Sep 2016 Status changed from active, no longer recruiting to completed.
- 08 Dec 2015 Results (n=13), presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
- 08 Oct 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.